Overview.- Pharmacoepidemiology of Diabetes.- New Definitions of Diabetes: Consequences.- Pharmacotherapy of Diabetes.- The Insulin Resistance Syndrome: Concept and Therapeutic Approaches.- Medical Emergencies - Diabetic Ketoacidosis and Hyperosmolar Hyperglycaemia.- Notes on the Use of Glucagon in Type 1 Diabetes.- Insulin and New Insulin Analogues, Insulin Pumps and Inhaled Insulin in Type 1 Diabetes.- Insulin and New Insulin Analogues with Focus on Type 2 Diabetes.- The Place of Insulin Secretagogues in the Treatment of Type 2 Diabetes in the Twenty-First Century.- Metformin - from Devil to Angel.- The Glitazones, Lessons so Far.- Antidiabetic Combination Therapy.- The Incretin Modulators - Incretin Mimetics (GLP-1 Receptor Agonists) and Incretin Enhancers (DPP-4 Inhibitors).- The Role of Alpha-Glucosidase Inhibitors (Acarbose).- Multifactorial Intervention in Type 2 Diabetes.- Treating the Comorbid Patient.- Obesity and Pharmacological Treatment.- Management of Diabetic Dyslipidaemia.- Coronary Intervention and Ischemic Cardioprotection in Diabetic Patients.- Diabetic Complications and Side-effects.- ACE-I and ARB and Blood Pressure Lowering, Including Effect on Renal Disease. Treatment of Advanced Diabetic Renal Disease.- Aspirin and Antiplatelet Drugs in the Prevention of Cardiovascular Complications of Diabetes.- Glycosylation Inhibitors, PKC Inhibitors and Related Interventions Against Complications.- Diabetic Foot Ulcers.- Pharmacotherapy in Diabetic Neuropathy.- Pregnancy - Pharmacological Problems.- Pharmacotherapy of Diabetic Retinopathy.- Pharmacotherapy in Diabetic Sexual Dysfunction.- A Bone Perspective.- Notes from Major Pharmaceutical Companies (all major companies asked to participate).- Achieving Guideline Control with New Pharmacotherapies: Albumin-Binding by Acylation of Insulin and GLP-1.- Pharmacotherapy of Diabetes.
Foreword.- Section: Overview.- Can we defeat the diabetic epidemic? Defining the world problem.- Diabetogenic, drugs, and medications with adverse metabolic effects.- New definitions of diabetes: consequences.- Milestones from the past and common misunderstandings.- Section: Pharmacotherapy of Diabetes.- Treatment of the metabolic syndrome today and tomorrow.- Treatment of diabetic catastrophes.- Insulin and new insulin analogues: inhaled insulin and insulin pumps in Type 1 diabetes.- Insulin and new insulin analogues in Type 2 diabetes.- New drugs and developments: pipeline drugs.- The increasing role of sulfonylurea, repaglinide and metformin.- The glitazones, lessons so far.- The incretin modulators.- Glycosylation inhibitors, PKC inhibitors and related interventions against complications.- The role of acarbose.- Multifactorial intervention in T2 diabetes.- Clinical trials in progress.- Section: Treating the Comorbid Patient.- Obesity and pharmacological treatment.- Lipid lowering.- Diabetes and cardiovascular disease.- Cardiology drugs for diabetic patients.- Aspirin and platelet active drugs.- ACE-Is and ARBs and blood pressure lowering, including effect on renal disease.- Section: Diabetic Complications.- Treatment of erectile and sexual dysfunction.- Stroke, diabetes, and glucose metabolism.- Foot ulcers.- Diabetic neuropathy.- Pregnancy - pharmacological problems.- Diabetic eye care.- Section: Guidelines.- Notes from drug agencies, professional organizations and pharmaeconomics.
Diabetes is a huge and growing healthcare worry, especially in Western countries. The treatment of both types - 1 and 2 - of this disease has changed radically over the past few years. This work provides an overview of all the changes that will come to be implemented in clinical practice. Summarizing all aspects of treatment, this book delineates the large amount of research work that has been completed over the last few years into the relief of complications in diabetes and vascular medicine in general.
The treatment of Type 1 and Type 2 diabetes has changed radically over the past few years. Not only there are now new opportunities for treating the key abnormality in diabetes, increased blood glucose, by effective agents such as new insulin preparations and oral agents. A completely new concept has emerged, namely the multifactorial intervention strategy. It appears that it may be more important to treat elevated blood pressure, eventually marginally elevated, and dyslipidemia. New results have really proven to be decisive in changing the outcome of the patients. However, some uncertainties still exist which means that clear reviews are needed.
Summarizing all aspects of treatment, much work has been completed over the last few years within the treatment of complications in diabetes, nephropathy, retinopathy, neuropathy, and vascular medicine in general. This work provides an overview of all these new changes to be implemented in clinical practice.